NCT03251105

Brief Summary

In this study, the Supreme and ProSeal LMAs in infants were compared by measuring their performance characteristics, including insertion features, ventilation parameters, induced changes in hemodynamics and rates of postoperative complications.

Trial Health

100
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
120

participants targeted

Target at P50-P75 for not_applicable surgery

Timeline
Completed

Started Apr 2016

Shorter than P25 for not_applicable surgery

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

April 27, 2016

Completed
8 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 31, 2016

Completed
1 month until next milestone

Study Completion

Last participant's last visit for all outcomes

January 31, 2017

Completed
6 months until next milestone

First Submitted

Initial submission to the registry

August 7, 2017

Completed
9 days until next milestone

First Posted

Study publicly available on registry

August 16, 2017

Completed
Last Updated

August 16, 2017

Status Verified

August 1, 2017

Enrollment Period

8 months

First QC Date

August 7, 2017

Last Update Submit

August 11, 2017

Conditions

Outcome Measures

Primary Outcomes (1)

  • performance characteristics

    insertion time in minutes

    operation duration

Secondary Outcomes (1)

  • haemodynamics

    operation duration

Study Arms (2)

ProSeal group

ACTIVE COMPARATOR

This group received the ProSeal LMA for supraglottic airway intubation and ventilation during anaesthesia.

Device: supraglottic airway intubation

Supreme group

ACTIVE COMPARATOR

This group received the Supreme LMA for supraglottic airway intubation and ventilation during anaesthesia.

Device: supraglottic airway intubation

Interventions

ProSeal groupSupreme group

Eligibility Criteria

AgeUp to 12 Months
Sexall
Healthy VolunteersYes
Age GroupsChild (0-17)

You may qualify if:

  • scheduled for elective, minor (\<1 hour duration), lower abdominal surgery, including unilateral herniorrhaphy and unilateral orchidopexy

You may not qualify if:

  • premature birth, potentially difficult airway, clinically significant upper respiratory tract infection and risk of aspiration, such as gastro-oesophageal reflux disease

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Related Publications (2)

  • Luce V, Harkouk H, Brasher C, Michelet D, Hilly J, Maesani M, Diallo T, Mangalsuren N, Nivoche Y, Dahmani S. Supraglottic airway devices vs tracheal intubation in children: a quantitative meta-analysis of respiratory complications. Paediatr Anaesth. 2014 Oct;24(10):1088-98. doi: 10.1111/pan.12495. Epub 2014 Jul 30.

    PMID: 25074619BACKGROUND
  • Oba S, Turk HS, Isil CT, Erdogan H, Sayin P, Dokucu AI. Comparison of the Supreme and ProSeal laryngeal mask airways in infants: a prospective randomised clinical study. BMC Anesthesiol. 2017 Sep 5;17(1):125. doi: 10.1186/s12871-017-0418-z.

Study Officials

  • Sibel Oba, MD

    Sisli Hamidiye Etfal Training and Research Hospital

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
NONE
Purpose
TREATMENT
Intervention Model
PARALLEL
Model Details: Infants, who were scheduled to undergo lower abdominal surgery and to receive anaesthesia
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Specialist, M.D.

Study Record Dates

First Submitted

August 7, 2017

First Posted

August 16, 2017

Study Start

April 27, 2016

Primary Completion

December 31, 2016

Study Completion

January 31, 2017

Last Updated

August 16, 2017

Record last verified: 2017-08

Data Sharing

IPD Sharing
Will not share

We can only share data as Exel or SSPS, but not with patient names.